• Orexo received a BARDA contract modification adding USD 2.99 million to extend OX390’s initial development phase through end-2027.
• Change lifts potential contract value to USD 53.8 million from USD 50.9 million, subject to milestones and deliverables.
• Funding supports additional FDA-required development work, including nonclinical safety and product testing for OX390.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.